Strategic partnerships Opportunity to accelerate AG10 commercialization through strategic partnerships with larger pharma, given a track record of collaboration (Alexion Japan) and demonstrated interest from major players such as GSK. Existing alliances indicate receptiveness to licensing or co-development deals, and AB Cardiologists insights suggest a path to reach target cardiology and neurology audiences early. BD approach: explore licensing, co-development, or distribution deals to expand US, EU, and JP reach.

Rare disease access Underserved ATTR patient community and payer access can be advanced via partnerships with patient advocacy groups and cardiology networks. The collaboration with Association of Black Cardiologists shows commitment to understanding patient channels; use this to inform recruitment, clinical trial enrollment, and payer education; propose value propositions to payers and health systems to support access to AG10 once approved.

Technology leverage Technology-driven marketing and field enablement create a platform for rapid, compliant product launch. With Salesforce and Veeva RIM, plus analytics tools like SAS/STAT and Spotfire, Eidos can leverage real-world data, forecasting, and physician segmentation to optimize market access, investigator site selection, and post-launch HEOR studies; offer data and analytics services to accelerate BD.

Financials and partnerships Small to mid-sized biotech with moderate funding and revenue signals potential for co-development or licensing partnerships to scale commercialization and global footprint; this is relevant to BridgeBio and potential acquirers; propose principal BD approach focusing on milestone-based deals, joint development, or regional commercialization rights.

Competitive positioning AG10 positioned as a potential best-in-class TTR stabilizer; highlight need to differentiate in a competitive landscape with existing therapies by emphasizing organ-specific outcomes, early access programs, and robust payer value narratives; pursue partnerships that bolster clinical data packages, comparative studies, and regional commercialization pathways.